Second Sight Medical Products, Inc. develops, manufactures and markets prosthetic devices. Its product the Argus II System, treats outer retinal degenerations and employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The firm's system works by converting video images captured by a miniature camera housed in a patient's glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina. The company was founded by Alfred E. Mann, Aaron Mendelsohn, Sam Williams, Robert J. Greenberg and Gunnar Bjorg in 1998 and is headquartered in Sylmar, CA.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EYES
CUSIPN/A
Phone(818) 833-5000
Debt
Debt-to-Equity RatioN/A
Current Ratio1.75
Quick Ratio1.24
Price-To-Earnings
Trailing P/E Ratio-2.81
Forward P/E Ratio-2.86
P/E GrowthN/A
Sales & Book Value
Annual Sales$7.96 million
Price / Sales13.99
Cash FlowN/A
Price / CashN/A
Book Value$0.14 per share
Price / Book11.86
Profitability
EPS (Most Recent Fiscal Year)($0.59)
Net Income$-28,510,000.00
Net Margins-418.82%
Return on Equity-432.45%
Return on Assets-232.22%
Miscellaneous
Employees112
Outstanding Shares67,070,000
Market Cap$127.44 million
Second Sight Medical Products (NASDAQ:EYES) Frequently Asked Questions
What is Second Sight Medical Products' stock symbol?
Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."
How were Second Sight Medical Products' earnings last quarter?
Second Sight Medical Products Inc (NASDAQ:EYES) released its quarterly earnings results on Tuesday, August, 7th. The medical device company reported ($0.12) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.14) by $0.02. The medical device company had revenue of $1.91 million for the quarter, compared to the consensus estimate of $2.21 million. Second Sight Medical Products had a negative return on equity of 432.45% and a negative net margin of 418.82%. View Second Sight Medical Products' Earnings History.
When is Second Sight Medical Products' next earnings date?
What price target have analysts set for EYES?
1 Wall Street analysts have issued 12-month price objectives for Second Sight Medical Products' stock. Their forecasts range from $5.00 to $5.00. On average, they expect Second Sight Medical Products' stock price to reach $5.00 in the next year. This suggests a possible upside of 201.2% from the stock's current price. View Analyst Price Targets for Second Sight Medical Products.
What is the consensus analysts' recommendation for Second Sight Medical Products?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Second Sight Medical Products in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Second Sight Medical Products.
Who are some of Second Sight Medical Products' key competitors?
Some companies that are related to Second Sight Medical Products include Cutera (CUTR), Electrocore (ECOR), BioLife Solutions (BLFS), Vision Sciences (CGNT), Semler Scientific (SMLR), Rockwell Medical (RMTI), Helius Medical Technologies (HSDT), Fonar (FONR), Zynex (ZYXI), Edap Tms (EDAP), Viveve Medical (VIVE), IRIDEX (IRIX), Stereotaxis (STXS), Soleno Therapeutics (SLNO) and Digirad (DRAD).
Who are Second Sight Medical Products' key executives?
Second Sight Medical Products' management team includes the folowing people:
- Jonathan Will McGuire, President, Chief Executive Officer & Director
- William Patrick Ryan, Chief Operating Officer
- John T. Blake, Chief Financial Officer & Secretary
- Edward Randolph, VP-Operations, Quality & Information Technology
- David Jacques, Vice President-Research & Development
When did Second Sight Medical Products IPO?
(EYES) raised $32 million in an IPO on Wednesday, November 19th 2014. The company issued 3,500,000 shares at $9.00 per share. MDB Capital Group, LLC served as the underwriter for the IPO.
How do I buy shares of Second Sight Medical Products?
Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Second Sight Medical Products' stock price today?
One share of EYES stock can currently be purchased for approximately $1.66.
How big of a company is Second Sight Medical Products?
Second Sight Medical Products has a market capitalization of $127.44 million and generates $7.96 million in revenue each year. The medical device company earns $-28,510,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. Second Sight Medical Products employs 112 workers across the globe.
What is Second Sight Medical Products' official website?
How can I contact Second Sight Medical Products?
Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342. The medical device company can be reached via phone at (818) 833-5000 or via email at [email protected]
MarketBeat Community Rating for Second Sight Medical Products (NASDAQ EYES)
MarketBeat's community ratings are surveys of what our community members think about Second Sight Medical Products and other stocks. Vote "Outperform" if you believe EYES will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYES will underperform the S&P 500 over the long term. You may vote once every thirty days.
